Next Article in Journal
The “Metabolic Memory” Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications
Previous Article in Journal
Snacking Quality Is Associated with Secondary School Academic Achievement and the Intention to Enroll in Higher Education: A Cross-Sectional Study in Adolescents from Santiago, Chile
Open AccessArticle

Effects of Vitamin D Supplementation on Bone Turnover Markers: A Randomized Controlled Trial

1
Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz 8036, Austria
2
Swiss Cardiovascular Center Bern, Department of Cardiology, Bern University Hospital, University of Bern, Bern 3011, Switzerland
3
Department of Internal Medicine, Division of Cardiology, Medical University of Graz, Graz 8036, Austria
4
Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen 32545, Germany
5
Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz 8036, Austria
6
Department of Internal Medicine, Division of Nephrology, Medical University of Graz, Graz 8036, Austria
7
Bad Gleichenberg Clinic, Bad Gleichenberg 8344, Austria
*
Author to whom correspondence should be addressed.
Nutrients 2017, 9(5), 432; https://doi.org/10.3390/nu9050432
Received: 22 March 2017 / Revised: 8 April 2017 / Accepted: 25 April 2017 / Published: 27 April 2017
Bone turnover markers (BTMs) are used to evaluate bone health together with bone mineral density and fracture assessment. Vitamin D supplementation is widely used to prevent and treat musculoskeletal diseases but existing data on vitamin D effects on markers of bone resorption and formation are inconsistent. We therefore examined the effects of vitamin D supplementation on bone-specific alkaline phosphatase (bALP), osteocalcin (OC), C-terminal telopeptide (CTX), and procollagen type 1 N-terminal propeptide (P1NP). This is a post-hoc analysis of the Styrian Vitamin D Hypertension Trial, a single-center, double-blind, randomized, placebo-controlled trial (RCT) performed at the Medical University of Graz, Austria (2011–2014). Two hundred individuals with arterial hypertension and 25-hydroxyvitamin D (25[OH]D) levels <75 nmol/L were randomized to 2800 IU of vitamin D daily or placebo for eight weeks. One hundred ninety-seven participants (60.2 ± 11.1 years; 47% women) were included in this analysis. Vitamin D had no significant effect on bALP (mean treatment effect (MTE) 0.013, 95% CI −0.029 to 0.056 µg/L; p = 0.533), CTX (MTE 0.024, 95% CI −0.163 to 0.210 ng/mL, p = 0.802), OC (MTE 0.020, 95% CI −0.062 to 0.103 ng/mL, p = 0.626), or P1NP (MTE −0.021, 95% CI −0.099 to 0.057 ng/mL, p = 0.597). Analyzing patients with 25(OH)D levels <50 nmol/L separately (n = 74) left results largely unchanged. In hypertensive patients with low 25(OH)D levels, we observed no significant effect of vitamin D supplementation for eight weeks on BTMs. View Full-Text
Keywords: vitamin D supplementation; bone turnover markers; osteocalcin; procollagen type 1 N-terminal propeptide; crosslaps; bone-specific alkaline phosphatase vitamin D supplementation; bone turnover markers; osteocalcin; procollagen type 1 N-terminal propeptide; crosslaps; bone-specific alkaline phosphatase
MDPI and ACS Style

Schwetz, V.; Trummer, C.; Pandis, M.; Grübler, M.R.; Verheyen, N.; Gaksch, M.; Zittermann, A.; März, W.; Aberer, F.; Lang, A.; Treiber, G.; Friedl, C.; Obermayer-Pietsch, B.; Pieber, T.R.; Tomaschitz, A.; Pilz, S. Effects of Vitamin D Supplementation on Bone Turnover Markers: A Randomized Controlled Trial. Nutrients 2017, 9, 432.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop